Key result
Ethosuximide treats human absence epilepsy primarily by blocking T-type calcium channels.
Why the study?
The role of calcium channel blockade in the antiepileptic action of ethosuximide, particularly its potency and efficacy, remains controversial.
Does ethosuximide block T-type calcium channels to exert antiepileptic action in absence epilepsy?
Does ethosuximide block T-type calcium channels to exert antiepileptic action in absence epilepsy?
Answers are grounded in this paper and cite their sources.
Ethosuximide exerts its antiepileptic action in human absence epilepsy largely through the blockade of T-type calcium channels.
The role of calcium channel blockade in the antiepileptic action of ethosuximide is controversial, especially regarding the potency and efficacy of block. However, recent evidence obtained from transgenic animals and heterologous expression systems supports a major role of T-type calcium channels in both the generation of absence seizures and the action of ethosuximide in human absence epilepsy.
No takes yet. Share an insight, caveat, or question.
John R. Huguenard (2002) studied this question. Ethosuximide exerts its antiepileptic action in human absence epilepsy primarily through the blockade of T-type calcium channels.
Synapse has enriched 10 related papers. Consider them for comparative context: